Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis
- PMID: 2286592
- DOI: 10.1093/jac/26.suppl_d.61
Pharmacokinetics of ofloxacin and adequacy of maintenance dose for patients on haemodialysis
Abstract
Seven patients, three females and four males, aged 33-70 years, with end-stage renal disease, on regular haemodialysis were treated for various infections with a loading dose of 200 mg and multiple maintenance doses of 100 mg ofloxacin per 24 h over ten days orally. The pharmacokinetics of ofloxacin were studied at the end of the treatment period before, during and after a haemodialysis session. Concentrations in plasma and dialysate were measured by HPLC. Mean trough concentration (+/- S.D.) of ofloxacin before the last drug intake was 1.6 (+/- 0.6) mg/l. At a Tmax of 1.5 (+/- 1.1) h a peak concentration of 3.1 (+/- 1.0) mg/l was reached. The mean half-lives of ofloxacin (+/- S.D.) which were determined in the dialysis-free interval (T1/2 beta) and during the haemodialysis session (T1/2HD) were 38.5 (+/- 14.1) h and 9.9 (+/- 3.4) h, respectively. Mean dialyser clearance (+/- S.D.) was 59.2 (+/- 15.4) ml/min and the fractional removal of ofloxacin amounted to 21.5 (+/- 8.2)%. The data show that in patients with regular haemodialysis treatment a loading dose of 200 mg orally and daily administration of 100 mg orally of ofloxacin results in therapeutically favourable and well tolerated plasma concentrations when given at the end of haemodialysis.
Similar articles
-
Multiple dose kinetics of ofloxacin and ofloxacin metabolites in haemodialysis patients.Eur J Clin Pharmacol. 1992;42(1):95-9. doi: 10.1007/BF00314927. Eur J Clin Pharmacol. 1992. PMID: 1541323
-
The pharmacokinetics of ofloxacin, desmethyl ofloxacin and ofloxacin N-oxide in haemodialysis patients with end-stage renal failure.J Antimicrob Chemother. 1988 Sep;22 Suppl C:65-72. doi: 10.1093/jac/22.supplement_c.65. J Antimicrob Chemother. 1988. PMID: 3182464
-
Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis.Int J Antimicrob Agents. 2008 Jul;32(1):46-9. doi: 10.1016/j.ijantimicag.2008.02.011. Epub 2008 Jun 4. Int J Antimicrob Agents. 2008. PMID: 18534825
-
Ofloxacin pharmacokinetics in chronic renal failure and dialysis.Clin Pharmacokinet. 1991 Nov;21(5):357-71. doi: 10.2165/00003088-199121050-00004. Clin Pharmacokinet. 1991. PMID: 1773550 Review.
-
[Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis].Ann Pharm Fr. 2004 May;62(3):177-85. doi: 10.1016/s0003-4509(04)94300-3. Ann Pharm Fr. 2004. PMID: 15243351 Review. French.
Cited by
-
Ofloxacin clinical pharmacokinetics.Clin Pharmacokinet. 1992 Jan;22(1):32-46. doi: 10.2165/00003088-199222010-00004. Clin Pharmacokinet. 1992. PMID: 1559306 Review.
-
Ofloxacin. A reappraisal of its antimicrobial activity, pharmacology and therapeutic use.Drugs. 1991 Nov;42(5):825-76. doi: 10.2165/00003495-199142050-00008. Drugs. 1991. PMID: 1723377 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical